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ABSTRACT
A population-based survey of invasive pneumococcal disease (IPD) was conducted among adults in
North-Rhine Westphalia, Germany. The study included 202 of the 386 hospitals in the region, together
with the 27 microbiological laboratories that submitted reports of IPD in these hospitals to the National
Reference Centre for Streptococci. The reports of 16 laboratories were comprehensively reviewed. Most
(95.8%) IPD isolates were susceptible to penicillin G, but 14.5% were resistant to clarithromycin.
Serotypes 14 (15.6%), 3 (9.3%), 4 (7.1%) and 7F (7.9%) were the most common. The serotype coverage of
the 23-valent pneumococcal polysaccharide vaccine was 80.8%. During 2001–2003, the annual incidence
of IPD, after correcting for laboratory and hospital under-reporting, was 16.2 ⁄ 100 000 in individuals
aged ‡ 65 years. In three university hospitals, blood cultures were obtained for only 37% of patients with
community-acquired pneumonia, and fewer than one-third of such cultures were obtained in one
hospital before antibiotics were prescribed, suggesting that the true incidence of IPD was closer to
50 ⁄ 100 000.
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INTRODUCTION
Streptococcus pneumoniae is a leading cause of
pneumonia, sepsis and meningitis among adults.
The mortality rates associated with invasive
pneumococcal disease (IPD) range from 5% to
35%, depending on the site of infection, patient’s
age and co-morbidity [1]. The possible prevention
of pneumococcal disease with capsular polysac-
charide vaccine has been studied for the past
90 years. Observational studies have shown that
vaccination with the 23-valent pneumococcal
polysaccharide vaccine prevents IPD in older
adults [2]. In Germany, pneumococcal vaccination
is recommended for elderly adults (aged
‡ 60 years) and for individuals with underlying
high-risk conditions [3]. However, doubts remain
about the value of pneumococcal vaccine, parti-
cularly its ability to provide long-term protection
and to prevent cases of non-bacteraemic pneu-
mococcal pneumonia [4–6].
Information regarding the annual incidence of
IPD is essential for estimating the health and
economic burden of pneumococcal disease, and
for implementing and evaluating programmes for
pneumococcal vaccination [7]. Such data are not
available for many countries, including Germany.
Furthermore, the future use of pneumococcal
conjugate vaccines in elderly high-risk adults will
require a detailed knowledge of the patterns of
antibiotic resistance and serotype distribution of
S. pneumoniae in this population [8]. The present
study analysed the antibiotic resistance proﬁles
and serotype distribution of isolates of S. pneu-
moniae from adults hospitalised with IPD in the
German state of North-Rhine Westphalia. The
incidence of IPD in different age groups, based on
actual reports and after adjusting for factors
contributing to the under-reporting of IPD, was
calculated.
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MATERIALS AND METHODS
Study population
In Germany, the National Reference Centre for Streptococci
(NRCS) has conducted nationwide prospective population-
and laboratory-based surveillance of IPD for several years
[8,9]. Surveillance for the current study focused on North-
Rhine Westphalia, the largest federal state in Germany, with
c. 18 million inhabitants. All 386 acute-care hospitals located in
the state were invited to participate in the study. Of these, 202
(52.2%) agreed. The 27 microbiological laboratories serving
these hospitals were identiﬁed, and all agreed to participate. A
feasibility study was conducted between March 2001 and June
2001. The main study was conducted during the 2-year period
from 1 July 2001 to 30 June 2003.
Hospitalised state residents aged ‡ 16 years were included
in the study. A case of IPD was deﬁned by the isolation of
S. pneumoniae from a normally sterile site. Each case was
considered to have occurred on the date the culture was
obtained. NRCS staff communicated regularly with all
microbiology laboratories serving the participating hospitals
to ensure that standardised case report forms were completed.
All suspected S. pneumoniae isolates were placed immediately
in transport medium (Port-A-Cul; Difco, Detroit, MI, USA) and
sent to the NRCS for species conﬁrmation (optochin sensitivity
and bile-solubility tests) and antimicrobial susceptibility
testing.
Antibiotic sensitivity testing and serotyping
MICs of penicillin G, amoxycillin, cefotaxime, clarithromycin,
clindamycin, tetracycline, gatiﬂoxacin, ciproﬂoxacin and
vancomycin were determined by the NCCLS microbroth
dilution method [10] using Mueller–Hinton broth (Difco)
supplemented with lysed horse blood (Oxoid, Wesel, Ger-
many) 5% v ⁄v. Plates were read after incubation at 35C for
20–24 h in ambient air. S. pneumoniae ATCC 49619 was used as
a reference strain. For determination of macrolide resistance
phenotypes, disks of erythromycin (15 lg) and clindamycin
(2 lg) (Oxoid) were placed 15–20 mm apart on Mueller–
Hinton agar (BBL Microbiology Systems, Cockeysville, MD,
USA) containing sheep blood (Oxoid) 5% v ⁄v. Plates were
inoculated with a swab dipped in a 0.5· McFarland standard
bacterial suspension [11].
Pneumococcal isolates were serotyped by Neufeld’s Quel-
lung reaction using type- and factor-speciﬁc antisera (Statens
Serum Institut, Copenhagen, Denmark).
Assessment of under-reporting of invasive pneumococcal
disease by laboratories and hospitals
Surveillance for IPD can be biased by under-reporting of IPD
cases by individual laboratories and hospitals. All 27 laborat-
ories were asked to provide complete laboratory records of all
cases of IPD, and 16 were able to do so. Data of all IPD isolates,
sent by each of these 16 laboratories to the NRCS, were linked
to the database of each laboratory’s information system,
thereby allowing the identiﬁcation of cases of microbiological-
ly conﬁrmed IPD that were not reported to the NRCS. Using
these data, a laboratory under-reporting factor (LUF) for each
laboratory (the number of all IPD isolates identiﬁed by the
laboratory divided by the number of isolates sent to the NRCS)
and a mean LUF for all 16 laboratories were calculated. A
hospital under-reporting factor (HUF) was also calculated by
dividing the number of beds in all hospitals in the state
(134 071) by the number of beds in the 202 participating
hospitals (70 605).
Determining the incidence of invasive pneumococcal disease
The estimated annual incidence of IPD for speciﬁc age groups
was calculated based on reports to the NRCS and population
data provided by the ‘Landesamt fu¨r Statistik’,
North-Rhine Westphalia (http://www.lds.nrw.de/statistik/
landesdatenbank.html). An incidence rate corrected for
laboratory and hospital under-reporting was also calculated
for each age group by multiplying the NRCS-derived incidence
rate by the LUF and the HUF.
Frequency of obtaining blood cultures and previous
antibiotic therapy in patients with community-acquired
pneumonia
For the year 2000, the frequency of obtaining blood cultures
was determined for patients admitted to three university
hospitals (Aachen, Du¨sseldorf and Cologne) with community-
acquired pneumonia (CAP). In addition, the frequency of
antibiotic treatment before blood cultures were obtained was
determined for CAP patients in 2001 by a detailed analysis of
patients’ histories. All cases with a diagnosis of CAP (all
diagnostic positions on the discharge summary) were identi-
ﬁed retrospectively on the basis of ICD-10 codes (J13, J15.9,
J18.0, J18.9). Cases were linked with data in the laboratory
information system of each hospital’s microbiological laborat-
ory. Outcome data were obtained for all patients from the
hospital discharge ﬁles of the individual hospitals.
RESULTS
Patient characteristics
During the 2-year study period, 647 IPD isolates
were obtained from adults and submitted to the
NRCS by the 27 microbiological laboratories. Of
these, 491 (75.9%) were from blood, 36 (5.6%) from
cerebrospinal ﬂuid, 54 (8.3%) from bronchial la-
vage ﬂuid, 30 (4.6%) from pleural punctures, and
36 (5.6%) from other normally sterile sites. Most
isolates (404; 62.4% of cases) were obtained from
patients aged ‡ 60 years, with 55.2% of all isolates
being obtained from male patients. Clinical diag-
noses were available for 404 of the 647 isolates, and
246 (60.6%) of these patients were diagnosed with
bacteraemic pneumococcal pneumonia.
Antibiotic sensitivity
Among all IPD isolates, 95.8% were susceptible to
penicillin G (MIC < 0.06 mg ⁄L), 3.9% were peni-
cillin-intermediate (MIC 0.1–1 mg ⁄L), and only
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0.3% were penicillin-resistant (MIC ‡ 2 mg ⁄L)
(Table 1). The combined rates of intermediate
resistance and resistance to amoxycillin and
cefotaxime were 0.2% and 0.9%, respectively.
Overall, 7.1% of isolates had reduced susceptibil-
ity to tetracycline, 4.1% to clindamycin and 15.1%
to clarithromycin. During the study period, an
increase in macrolide resistance was observed
(13.0% in year 1; 16.5% in year 2). Of the
clarithromycin-non-susceptible isolates (n = 98),
25 and 73 showed the MLSB and M phenotypes,
respectively. Only 0.1% of isolates were gatiﬂ-
oxacin-intermediate, and all were susceptible to
telithromycin and vancomycin (Table 1).
Serotype distribution and coverage by
pneumococcal vaccines
The leading serotypes were serotypes 14 (15.6%),
3 (9.3%), 7F (7.9%) and 4 (7.1%) (Table 2).
Serotype coverage by the 23-valent polysaccha-
ride vaccine was 80.8% for all age groups and
82.1% for the group aged ‡ 65 years. Serotype
coverages by the 7- and 11-valent conjugate
vaccines were 47.4% and 64.1%, respectively.
Under-reporting of invasive pneumococcal
disease by laboratories and hospitals
Of the 27 laboratories, 16 were able to provide
information for all their IPD isolates (Table 3).
These 16 laboratories submitted 476 (73.6%) of 647
isolates sent to the NRCS. However, according to
information systems in these 16 laboratories, 884
cases fulﬁlled inclusion criteria for IPD, indicating
that 408 (46.2%) of IPD isolates had not been sent
to the NRCS. From this, a mean LUF was
Table 1. Antibiotic sensitivities of 647 pneumococcal iso-
lates from adults with invasive pneumococcal disease in









Penicillin G £ 0.016–2 0.03 3.9 0.3 0.12–1 ‡ 2
Amoxycillin £ 0.016–2 0.03 0.2 0.0 4 ‡ 8
Cefotaximea £ 0.016–2 0.016 0.8 0.1 2 ‡ 4
Clarithromycin £ 0.06 to ‡ 32 4 0.6 14.5 0.5 ‡ 1
Clindamycin £ 0.06 to ‡ 32 0.06 0.2 3.9 0.5 ‡ 1
Telithromycin £ 0.016–0.5 0.06 0.0 0.0 2 ‡ 4
Tetracycline 0.06 to ‡ 32 1.0 0.3 6.8 4 ‡ 8
Gatiﬂoxacin £ 0.016–2 0.25 0.2 0.0 2 ‡ 4
Ciproﬂoxacinb 0.25–4 2.0 0.0 0.3 – ‡ 4
Vancomycin 0.06–1 0.5 0.0 0.0 – –
I, intermediately-resistant; R, resistant.
aBreakpoints for cefotaxime (meningitis): 1 mg ⁄L, ‡ 2 mg ⁄L.
bCiproﬂoxacin breakpoints have not been published by the NCCLS; a breakpoint of
‡ 4 mg ⁄L was used [16,17].
Table 2. Serotype distribution of Streptococcus pneumoniae
isolates from adults with invasive pneumococcal disease in
North-Rhine Westphalia, Germany, 2001–2003
Rank Serotype Number Percentage
Cumulative
percentagea
1 14 101 15.6 15.6
2 3 60 9.3 24.9
3 4 46 7.1 32.0
4 7F 43 6.6 38.6
5 23F 38 5.9 44.5
6 1 33 5.1 49.6
7 9V 30 4.6 54.3
8 6A 29 4.5 58.7
9 8 24 3.7 62.4
10 19F 21 3.2 65.7
11 6B 21 3.2 68.9
12 12F 18 2.8 71.7
13 18C 14 2.2 73.9
14 11A 13 2.0 75.9
15 9N 13 2.0 77.9
16 22F 12 1.9 79.8
17 9A 12 1.9 81.6
18 10A 10 1.5 83.2
19 9L 10 1.5 84.7
20 24F 9 1.4 86.1
21 17F 7 1.1 87.2
22 19A 7 1.1 88.3
23 31 7 1.1 89.3
Othersb 67 10.4 99.7
NT 2 0.3 100.0
Total 647 100.0
NT, non-typeable.
aCoverage of the 7-valent (11-valent) pneumococcal conjugate vaccine by age group:
16–35 years, 46.5% (67.4%); 35–65 years, 47.2% (62.4%); > 65 years, 47.8% (65.4%);
all ages, 47.4% (64.2%). The 7-valent conjugate vaccine strains included serotypes 4,
6B, 9V, 14, 18C, 19F and 23F. The 11-valent vaccine includes the 7-valent vaccine
types plus additional serotypes 1, 3, 5 and 7F. Coverage of the 23-valent
pneumococcal conjugate vaccine by age group: 16–35 years, 76.4%; 35–65 years,
80.1%; > 65 years, 82.1; all ages, 80.8%. Serotypes in the 23-valent polysaccharide
include the 11-valent serotypes plus serotypes 2, 6A, 8, 9N, 10A, 11A, 12F, 15B, 17F,
19A, 20, 22F and 33F.
bOthers include the following types (no. of isolates): 35F (6); 5 (6); 16F (5); 20 (5); 38
(5); 33F (4); rough (4); 13 (3); 15A (3); 15B (3); 23A (3); 28A (3); 7C (3); 12A (2); 12B (2);
15C (2); 15F (1); 23B (1); 25F (1); 29 (1); 34 (1); 35C (1); 36 (1); and 37 (1).
Table 3. Under-reporting of invasive pneumococcal dis-










6 130 107 1.21
13 224 62 3.61
7 59 59 1.00
11 64 56 1.14
10 36 36 1.00
3 89 33 2.70
15 42 27 1.56
9 22 22 1.00
12 71 17 4.18
2 29 13 2.23
16 24 12 2.00
4 71 9 7.89
8 9 9 1.00
1 6 6 1.00
14 6 6 1.00
5 2 2 1.00
Total 884 476 1.86
LUF, the number of isolates actually obtained divided by the number of isolates
reported to the NRCS.
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calculated of 1.86 (Table 3). It was assumed that
the same LUF would apply to the 11 other
laboratories. The HUF (see Methods) was 1.90.
Incidence of invasive pneumococcal disease
The estimated annual incidences of IPD are
shown in Table 4. For individuals aged ‡ 65 years,
the estimated incidence, based on reports to the
NRCS, was 4.6 ⁄ 100 000. After correcting for
laboratory and hospital under-reporting, the esti-
mated incidence in elderly individuals was
16.2 ⁄ 100 000.
Frequency of obtaining blood cultures and of
previous antibiotic therapy in patients with
community-acquired pneumonia
During 2000, 1254 patients with CAP were hos-
pitalised in three participating hospitals (Table 5).
Blood cultures were obtained for c. 50% of CAP
patients in two of these hospitals, but for only
14.8% of CAP patients in the third hospital.
Overall, blood cultures were obtained for 37.0%
of CAP patients, but only 11 (2.4%) blood cultures
were positive for S. pneumoniae.
In addition, the history of previous antibiotic
treatment was evaluated in one university hospi-
tal for 112 randomly selected CAP patients. Of
these, blood cultures were obtained for 46 (41.1%)
patients, but 12 (26.1%) were already being
treated with antibiotics when the cultures were
obtained (Table 6). Thus, only 34 (30.4%) of the
112 CAP patients had cultures taken that could
have conﬁrmed the presence or absence of bac-
teraemic pneumococcal pneumonia.
DISCUSSION
Surveillance of IPD has been ongoing in Germany
since the early 1990s, but most reports have
focused on infections in children [9,12,13]. The
present study was undertaken to gain an under-
standing of the epidemiology of IPD in adults,
including the antibiotic susceptibility of invasive
isolates, and the serotype distribution and inci-
dence of invasive disease in speciﬁc age groups.
Previous reports from Germany have documen-
ted a relatively low level of resistance to b-lactams
among S. pneumoniae isolates, and a very low
frequency of penicillin-resistant strains. These
ﬁndings were conﬁrmed in the current study;
3.9% of isolates were penicillin-resistant or -inter-
mediate, and only 0.3% were penicillin-resistant.
No signiﬁcant differences were observed between
the levels of b-lactam resistance in S. pneumoniae
Table 4. Estimated incidence of invasive pneumococcal









on reports to the





> 16–44 51 71.4 0.7 2.5
45–64 111 46.1 2.4 8.5
65–74 74.5 10.9 6.8 24.1
75–84 55 18.8 2.9 10.3
‡ 85 21 3.0 7.1 25.1
‡ 65 150.5 32.9 4.6 16.2
Total 463 150.4 3.079 10.87
aLandesamt fu¨r Statistik, North-Rhine Westphalia (http://www.lds.nrw.de/statis-
tik/landesdatenbank.html).
bThe adjusted estimated incidence was calculated by multiplying the number of
cases by the laboratory under-reporting factor (LUF) and the hospital under-
reporting factor (HUF). See text for details.
Table 5. Blood culture rates for 1254 adults with community-acquired pneumonia (CAP) in three university hospitals in





















1a 302 168 55.6 53 17.5 5 1.7 15.6
2 494 228 46.2 57 11.5 4 0.8 14.2
3 458 68 14.8 42 9.2 2 0.4 9.2
Total 1254 464 37.0 152 12.1 11 1.0 13.0
aIn this university hospital, the rate of previous antibiotic treatment was determined for 112 of the 168 patients from whom cultures were obtained.
Table 6. Relationship between blood cultures and previ-
ous antibiotic treatment in 112 patients hospitalised with
community-acquired pneumonia in North-Rhine West-
phalia, Germany, 2001
Previous antibiotic treatment (%)
Yes No Total
Blood culture obtained (%)
Yes 10.7 30.4 41.1
No 13.4 45.5 58.9
Total 24.1 75.9 100.0
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isolates obtained from adults and those reported in
earlier studies of children. In a separate popula-
tion-based study of IPD in German children, von
Kries et al. [9] reported that 3.3% of invasive
isolates had intermediate susceptibility to penicil-
lin, but that none was resistant.
In contrast to these low levels of resistance to
b-lactams, the present study found that levels of
macrolide resistance among pneumococci were
increasing. More than 15% of invasive isolates
from adults were clarithromycin-resistant, con-
ﬁrming ﬁndings of earlier studies in adults [12]
and children [9]. Moreover, a relatively high rate
of M phenotype strains among macrolide-resist-
ant isolates in Germany has been reported [14].
The increase in macrolide resistance in Germany
is worrisome and underscores the need to add
pneumococcal conjugate vaccine to the German
childhood vaccination programme. In the USA,
macrolide resistance among isolates causing inva-
sive pneumococcal disease increased steadily
from 4.5 ⁄ 100 000 in 1994 to 9.3 ⁄ 100 000 in 1999.
Following the introduction of childhood vaccin-
ation in 2001, this frequency fell to 2.9 ⁄ 100 000 in
2002 [15]. This experience indicates that vaccin-
ation with pneumococcal conjugate vaccine can
be an effective strategy for reducing antibiotic
resistance in a community.
The level of ﬂuoroquinolone resistance detected
(0.3%) was signiﬁcantly lower than the levels
reported from Canada [16] and Spain [17]. Newer
ﬂuoroquinolones with greater potency against
S. pneumoniae (e.g., levoﬂoxacin and moxiﬂoxacin)
have been licensed recently in Europe. Because of
the emergence of antimicrobial resistance in
pneumococci [18], these agents are now recom-
mended for the empirical treatment of pneumonia
in adults when resistance is suspected [19]. In
several countries, ﬂuoroquinolones are also
recommended for initial empirical therapy of
selected outpatients with community-acquired
respiratory tract infections (e.g., patients with
acute exacerbations of chronic bronchitis) [19,20].
Pneumococcal resistance to quinolones is caused
by mutations in either parC or gyrA, or both [21].
Strains become fully ﬂuoroquinolone-resistant
following a second mutation in the other target
gene (either gyrA or parC). Some strains with
ciproﬂoxacin MICs ‡ 4 mg ⁄L and mutations in the
quinolone resistance-determining regions remain
susceptible to newer ﬂuoroquinolones, but the
therapeutic value of newer quinolones for infec-
tions caused by these strains needs further inves-
tigation.
The level of tetracycline resistance (6.8%) was
lower than the levels observed in the early 1990s
[22]. Marked differences in antibiotic susceptibil-
ity among pneumococcal isolates have been
reported from several European countries [23].
Among the possible responsible factors, different
levels of antibiotic consumption may be among
the most important [24,25]. Goossens et al. [26]
reported higher rates of antibiotic resistance in
southern and eastern Europe than in northern
Europe, probably caused by the higher consump-
tion of antibiotics in southern and eastern Europe.
Serotypes 14, 3, 4, 7F, 23F and 1 were the
leading serotypes responsible for IPD in adults. In
other European countries, the serotype distribu-
tion varies, but overall the coverage provided by
the 23-valent pneumococcal polysaccharide vac-
cine is relatively stable, ranging from 80% to
‡ 90% [2]. It is notable that a relatively high rate of
serotype 1 infections was found, which conﬁrms
the ﬁndings of other investigators [27].
An evaluation of temporal trends in the sero-
group distribution of invasive isolates obtained in
the USA between 1928 and 1998 revealed that the
proportion of infections caused by serogroups
included in the 7-valent pneumococcal conjugate
vaccine increased from 15% to 59% during this
period [28]. In contrast, the proportion of infec-
tions caused by the ‘epidemic’ serogroups (1, 2, 3
and 5) decreased from 71% to 7% in adults, and
from 18% to 2% in children. Socio-economic
factors, such as crowded living conditions, prob-
ably promoted outbreaks of epidemic serogroup
disease, but these factors have become less com-
mon, favouring the transmission of ‘paediatric’
serotypes, rather than epidemic serogroups, from
children to adults [28]. The present ﬁndings from
Germany are compatible with this hypothesis.
The efﬁcacy of the 23-valent pneumococcal poly-
saccharide vaccine has not been demonstrated for
non-invasive pneumococcal disease in elderly
and high-risk adults [2,6], but it might be useful
in this group. In contrast, the current 7-valent
conjugate vaccine might be inadequate, as only
47.4% of IPD isolates were covered by the 7-
valent vaccine. The relatively low coverage of
adult serotypes by the 7-valent vaccine has also
been reported from other countries [8].
Epidemiological studies based solely on labor-
atory surveillance can be biased because of under-
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reporting. Thus, for every case of IPD reported to
the NRCS, almost one additional case went
unreported (mean LUF = 1.86). This ﬁnding is
similar to that of an earlier nationwide study of
IPD in children that used a capture–recapture
method to analyse laboratory- and hospital-based
surveillance data [9]. Laboratory-based surveil-
lance failed to detect c. 50% of these IPD cases.
The present study is the ﬁrst to attempt to
estimate the incidence of IPD for adults in
Germany. As in other countries, IPD is relatively
infrequent among younger adults. After correc-
tion for laboratory and hospital under-reporting,
the incidence was 0.9–4.0 ⁄ 100 000 in individuals
aged < 50 years. Above this age, the incidence
increased substantially to 16.2 ⁄ 100 000 in indivi-
duals aged ‡ 65 years. Similar ﬁndings have been
reported for this age group from England and
Wales (21 ⁄ 100 000), France (18 ⁄ 100 000) and
Sweden (27 ⁄ 100 000), although much higher rates
have been reported from Denmark (64 ⁄ 100 000),
The Netherlands (63 ⁄ 100 000), Norway
(62 ⁄ 100 000) and Spain (57 ⁄ 100 000) [2].
The large variations (more than three-fold) in
the reported incidence of IPD between different
countries, and even greater differences between
regions within individual countries, do not seem
to be related to real variations in the magnitude of
disease occurrence, but rather to differences in
surveillance systems and the ascertainment of
individual cases [2]. In the present study, blood
cultures were obtained from only 37% of CAP
patients in three university hospitals, and, in one
hospital, less than one-third of all CAP patients
had a blood culture taken before being treated
with antibiotics, meaning that only in this group
could the presence or absence of bacteraemic
pneumococcal pneumonia be determined accu-
rately. It is unlikely that the other two hospitals
differed in this respect. The failure to obtain
blood cultures for most patients hospitalised with
CAP has been reported previously in the UK [2].
In addition, a study in Italy [29] found that
incidence rates for invasive pneumococcal disease
in individuals aged ‡ 65 years were 5.7 and
0.2 ⁄ 100 000, respectively, but that only 27% and
7%, respectively, of hospitalised patients with
pneumonia had either blood or cerebrospinal
ﬂuid cultures taken. Thus, it seems to be a
common ﬁnding that only about one-third of
CAP patients have a blood culture taken before
the use of antibiotics.
A retrospective study in Germany found that
blood cultures were taken frequently for children
with sepsis (96%) and meningitis (95%), but less
frequently for those with pneumonia (49%) and
fever without focus (48%) [30]. In addition, a
prospective study of adults hospitalised with
CAP in ﬁve centres in Canada, the USA, the UK,
Spain and Sweden showed that previous anti-
biotic treatment and rates of obtaining blood
cultures for CAP patients varied considerably
among countries, and that the incidence of IPD
could be under-reported by a factor of at least two
[31]. Blood culture sampling rates might be too
low to provide a sensitive indication of the
incidence of IPD in children, perhaps more so in
Europe than in the USA [30,32], and the same
seems to be true for older adults. This may help to
explain the large differences between the reported
incidence of IPD among adults in the USA and
those reported in several European countries.
In conclusion, the present study revealed that
the incidence of IPD for individuals aged
‡ 65 years, corrected for laboratory and hospital
under-reporting, was 16.2 ⁄ 100 000. Bacteraemic
pneumococcal pneumonia accounts for c. 80–90%
of all invasive pneumococcal disease in most case
series [2], but only 60.6% of the isolates sent to the
NRCS listed pneumonia as the clinical diagnosis.
In addition, blood cultures were obtained from
only about one-third of CAP patients and, in many
cases, were probably obtained after, rather than
before, antibiotic treatment was started. These
ﬁndings indicate strongly that IPD was under-
reported, and that the true incidence of IPD in this
age group was probably close to 50 ⁄ 100 000 [2].
The level of b-lactam resistance among IPD isolates
in German adults was still low, but increasing
resistance to macrolides is of concern. As in other
countries, the serotype coverage by the 23-valent
vaccine for IPD in adults is high. Correcting for
under-reporting, the incidence of IPD in elderly
adults is comparable to that in many other coun-
tries. These ﬁndings provide a solid evidence base
for current pneumococcal vaccination recommen-
dations for adults in Germany.
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